Bluejay Diagnostics Reports Q1 Financials, Confirms Short Cash Runway Amid Operational Progress

summarizeSummary

Bluejay Diagnostics reported $3.7 million in cash as of March 31, 2026, with a net loss of $1.9 million for Q1, indicating a short cash runway, despite progress in its SYMON-II clinical study and manufacturing readiness.

check_boxKey Events · Financing and Capital Events · BJDX

• Q1 2026 Financials

  Reported cash and cash equivalents of $3.7 million as of March 31, 2026, with a net loss of $1.9 million for the quarter.

• Short Cash Runway Confirmed

  The current cash position, combined with the burn rate, suggests a runway of less than two quarters, reinforcing the "going concern" warning from the recent 10-K.

• Clinical Study Nearing Completion

  Advanced enrollment in the SYMON-II pivotal clinical study, reaching approximately 680 out of 750 target patients.

• Manufacturing & Regulatory Progress

  Resolved technical issues in Symphony cartridge manufacturing and continues to pursue FDA 510(k) submission for its IL-6 test.

auto_awesomeAnalysis · BJDX · Industrial Applications And Services

This 8-K provides a critical update on Bluejay Diagnostics' financial health, confirming a precarious cash position of $3.7 million as of March 31, 2026. With a quarterly net loss of $1.9 million, the company's cash runway is estimated to be less than two quarters, reinforcing the "going concern" warning from its recent 10-K. While the company reported positive operational progress in its SYMON-II clinical study (nearing full enrollment) and manufacturing readiness for its Symphony IL-6 test, these advancements do not alleviate the immediate and substantial need for new capital. Investors should note the continued financial pressure, especially in light of the upcoming reverse stock split vote aimed at preventing Nasdaq delisting.